Bilirubin

Global Infant Phototherapy Device Market Report to 2030 - Players Include GE Healthcare, Natus Medical and Ningbo David Medical Device Among Others

Retrieved on: 
Monday, June 20, 2022
Quartz, STI, Skin, LTD, CAGR, Infant, General Electric Company, Imp, Light therapy, Method, Hemolysis, Sepsis, Bilirubin, Oil lamp, Hospital, Light, Jaundice, Growth, Bruise, Urine, Configuration, Andrews v Gas Meter Co, Light-emitting diode, Prevalence, National Collaborating Centre for Mental Health, Electric light

The global infant phototherapy device market was valued at $ 91,930.50 thousands in 2020, and is projected to reach $ 132,077.53 thousands by 2030, registering a CAGR of 3.7% from 2021 to 2030.

Key Points: 
  • The global infant phototherapy device market was valued at $ 91,930.50 thousands in 2020, and is projected to reach $ 132,077.53 thousands by 2030, registering a CAGR of 3.7% from 2021 to 2030.
  • The major factors that drive the growth of the global infant phototherapy device market include rise in prevalence of neonatal jaundice and advantages of phototherapy over other treatment methods.
  • The infant phototherapy device market is segmented on the basis of type of light lamp, configuration, end user, and region.
  • Ltd., Natus Medical Incorporated, Ningbo David Medical Device Co., LTD., Novos Medical Devices San.

Insights on the Infant Phototherapy Device Global Market to 2030 - by Light Source, Configuration, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Friday, June 17, 2022
Nursing, Health, Medical Devices, Consumer, Hospitals, Health Technology, Baby, Maternity, CAGR, Skin, Infant, Light therapy, Method, Hemolysis, Sepsis, Bilirubin, Hospital, Light, Jaundice, Growth, Bruise, Urine, Light-emitting diode, Prevalence, National Collaborating Centre for Mental Health

The "Infant Phototherapy Device Market: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infant Phototherapy Device Market: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global infant phototherapy device market is expected to grow at a CAGR of 3.7% from 2021 to 2030.
  • The major factors that drive the growth of the global infant phototherapy device market include rise in prevalence of neonatal jaundice and advantages of phototherapy over other treatment methods.
  • The infant phototherapy device market is segmented on the basis of type of light lamp, configuration, end user, and region.

CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Retrieved on: 
Monday, May 23, 2022
Wayne State University, Assistant, Risk, Death, Risk assessment, SD, Population, Henry Ford Health System, Conditional sentence, Research, Survival, DDW, Doctor of Philosophy, Transplant, Cirrhosis, Poster, Erasmus MC, PBC, NASDAQ, Phase II, Therapy, Non-cirrhotic portal fibrosis, Associate, Liver, University of Toronto, UDCA, Toronto Centre, Hepatology, ALT, Primary biliary cholangitis, INR, NL, University, Division, Wayne, Henry Ford, OCA, Liver disease, Alkaline phosphatase, ALP, Bilirubin, Gastrointestinal disease, NCT, GI, Patient Centered Primary Care Collaborative, MD, CA, Pharmaceutical industry, Medicine, Patient, Biostatistics, Safety, GLOBE

Data were presented demonstrating that seladelpar treatment throughout 2 years resulted in a decrease in PBC GLOBE score and predicted improved transplant-free survival.

Key Points: 
  • Data were presented demonstrating that seladelpar treatment throughout 2 years resulted in a decrease in PBC GLOBE score and predicted improved transplant-free survival.
  • The GLOBE score is a validated risk assessment tool providing an estimate of transplant-free survival for patients with PBC.
  • In this analysis, the GLOBE score was used to measure response to seladelpar treatment for predicting long-term survival outcomes for patients with PBC.
  • Efficacy, safety, and tolerability of seladelpar in PBC patients with compensated cirrhosis were comparable to that of non-cirrhotic patients.

Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

Retrieved on: 
Monday, May 9, 2022
People, Aspartate transaminase, Interim, QT interval, Osteogenesis imperfecta, ULN, Biomarker, Safety, Cystic fibrosis, Șaeș, Degenerative disease, Cough, Atalanta, Annual report, Death, Respiratory disease, Bronchiectasis, Respiratory tract, Standard of care, Forward-looking statement, Headache, AES, AATD, Bilirubin, Company, FEV1, Plasma, WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents, AST, Patient, Infection, COPD, Fibrosis, Desmosine, Ovarian cancer, CF, AAT, U.S. Securities and Exchange Commission, LSM, Neoplasm, Interest group, Security (finance), Adverse Events, Form 6-K, COVID-19, Arm, BOS, Monaco Age Oncologie, Therapy, History, OI, AE, Medical imaging, Pharmaceutical industry, Alanine transaminase, AstraZeneca

LONDON and REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced positive top-line efficacy and safety results from “ASTRAEUS” a Phase 2 study of the investigational oral neutrophil elastase (NE) inhibitor, alvelestat (MPH-966), in patients with severe alpha-1 antitrypsin deficiency-associated emphysema.

Key Points: 
  • Consistent with the known safety profile of alvelestat, no safety signals were observed in adverse event (AE) monitoring.
  • Most AEs were mild to moderate, including within Adverse Events of Special Interest (AESI) which were observed in 23 subjects.
  • Prior to Mereo BioPharma licensing alvelestat from AstraZeneca (AZ), trials across COPD, bronchiectasis and cystic fibrosis (CF) had been performed.
  • Mereo reported a positive Phase 1b/2 trial in COVID-19 which was completed in 2021 and showed alvelestat was safe and well tolerated.

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

Retrieved on: 
Thursday, May 5, 2022
Drug development, Assistant professor, Prevalence, Fatty liver disease, Degenerative disease, Human, Risk, Hospital, Administration, New Enterprise Associates, Massachusetts General Hospital, GH, SEC, CEO, Veni, vidi, vici, Woman, NASDAQ, Bilirubin, Private Securities Litigation Reform Act, Patient, Fibrosis, FDA, Letter, Incidence, Uncertainty, Pandemic, Disease, NASH, Nass, Liver, Hypothalamus, Body composition, NEA, Optimism, Population, IND, Physician, Growth hormone, Liver disease, Non-alcoholic fatty liver disease, MD, Growth, Man, LUMO, Department, Orphan, GLOBE, UCB, Therapy, Lipolysis, Adult, Biological activity, Harvard Medical School, Pharmaceutical industry, Dietary supplement, Public relations, Lumos, NAFLD, EU, Science

Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.

Key Points: 
  • Lumos Pharma is honored to partner with Dr. Dichtel and Massachusetts General Hospital to evaluate LUM-201 in NAFLD, commented Rick Hawkins, CEO and Chairman of Lumos Pharma.
  • Nonalcoholic fatty liver disease is estimated to be prevalent in approximately 25% of adults worldwide.
  • This investigator-initiated Phase 2 trial is a single-site, 6-month, open-label pilot study of daily oral LUM-201 in adults with NAFLD.
  • The trial will evaluate a dose of 25 mg/day of LUM-201 in 10 men and women with NAFLD.

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

Retrieved on: 
Monday, April 4, 2022
Private Securities Litigation Reform Act, Company, Therapy, ACC, Population, Apolipoprotein, Triglyceride, Moyamoya disease, Biotechnology, Research, Liver, PCSK9, Program, ALT, Cardiovascular disease, Bilirubin, U.S. Securities and Exchange Commission, Gene editing, Goal, American College, Cardiology, Nasdaq, GLOBE, Gene, Solution, Blood, Patient, Security (finance), Vaccine, Pharmaceutical industry, ANGPTL3, Verve

CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, reported updated preclinical data in non-human primates (NHPs) showing durable and well-tolerated editing of the ANGPTL3 gene following administration of the company’s ANGPTL3 base editor, supporting its potential as a treatment for atherosclerotic cardiovascular disease (ASCVD). In addition, the company provided an update on its sequential dosing research efforts, demonstrating that administration of a PCSK9 base editor followed by an ANGPTL3 base editor was durable and well-tolerated in NHPs. The data are being presented today during an oral session at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC 2022).

Key Points: 
  • The data are being presented today during an oral session at the American College of Cardiology 71st Annual Scientific Session & Expo (ACC 2022).
  • We are pleased to see durable editing now out to nearly two years in NHPs following a single administration of an ANGPTL3 base editor, which we believe could offer a gene editing treatment solution for multiple patient populations.
  • Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines.
  • VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

Retrieved on: 
Tuesday, February 8, 2022
NASDAQ, CE marking, Liver disease, Adsorption, Office of Inspector General, U.S. Department of Health and Human Services, National Heart, Lung, and Blood Institute, Private Securities Litigation Reform Act, Cardiopulmonary bypass, Cytokine release syndrome, SOCOM, DOAC, Company, Facebook, Twitter, Myoglobin, Cytokine adsorbing column, Army of the United States, Annual report, Ticagrelor, Union, Risk, Investor relations, NIH, FDA, Patient, U.S. Department of Defense Strategy for Operating in Cyberspace, Air Force Materiel Command, National, Professional corporation, DARPA, Adult, Cytosorbents Corporation, Blood, HHS, SEC, Death, Rivaroxaban, Trauma, Federal, Bilirubin, NHLBI, Safe, United, Lung, United States Special Operations Command, Judgement, Manifest and latent functions and dysfunctions, COVID-19, Pharmaceutical industry

It is recommended that participants dial in approximately 10 minutes prior to the start of the call.

Key Points: 
  • It is recommended that participants dial in approximately 10 minutes prior to the start of the call.
  • An archived recording of the conference call will be available under the Investor Relations portion of the company's website at https://cytosorbents.com/investor-relations/financial-results/ .
  • CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
  • This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995.

FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease

Retrieved on: 
Friday, February 4, 2022
NASDAQ, Private Securities Litigation Reform Act, Part, Forward-looking statement, Cold agglutinin disease, Intellectual property, Regulation, Medicine, Blood transfusion, Part-time jobs in South Korea, Science, Solution, Indigestion, Research, Acquisition, Annual report, Immune system, SNY, Rupture, Marketing, ULN, Cough, Human, Sutimlimab, Respiratory tract infection, Complement component 1s, Chest pain, SAN, FDA, Patient, AMF, Form 20-F, Safety, Peripheral edema, Anemia, Oxygen, SEC, Autoimmune hemolytic anemia, Degenerative disease, Streptococcus, Hemolysis, Bilirubin, SE, History, CAD, Georgetown Lombardi Comprehensive Cancer Center, Social responsibility, Diarrhea, Weakness, Insurance, Arthritis, Fatigue, Antibody, Arthralgia, COVID-19, Vaccine, Pharmaceutical industry, Health insurance, Sanofi

Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.

Key Points: 
  • Enjaymo is the only approved treatment to inhibit red blood cell destruction in CAD and help stop the chain reaction from the start.
  • For the first time, we have a treatment that targets complement-mediated hemolysis, which is the underlying cause of the red blood cell destruction in many CAD patients.
  • Dosage interruptions due to an adverse reaction occurred in 17 percent (4/24) of patients who received Enjaymo.
  • Following the completion of the 26-week treatment period of CARDINAL (Part A), eligible patients continued to receive Enjaymo in an extension study.

Bon Secours Liver Institute of Richmond Participating in RESPONSE, a Global Phase 3 Clinical Research Study Evaluating an Investigational Therapy for the Treatment of Primary Biliary Cholangitis (PBC)

Retrieved on: 
Thursday, February 3, 2022
Urine, Swelling, Bilirubin, Safety, Risk, Patient, Digestive, Fatty liver disease, UDCA, Liver disease, ULN, National Institute of Diabetes and Digestive and Kidney Diseases, Liver cancer, Food, ALP, Liver, Bile, Hepatocellular carcinoma, Liver transplantation, EMA, Cirrhosis, Bon, Primary biliary cholangitis, Itch, Pakistan Kidney and Liver Institute, Cholestasis, Inflammation, Abdominal pain, Breakthrough therapy, Alkaline phosphatase, Kidney, Weakness, Jaundice, Bon Secours Health System, Diarrhea, Health, European Medicines Agency, PBC, Travel, GLOBE, National Institute, Institute of Liver and Biliary Sciences, Nausea, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, Hepatitis, Weight loss, Pharmaceutical industry, Medical imaging, Diabetes

RICHMOND, Va., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Bon Secours Liver Institute of Richmond is enrolling participants into RESPONSE, a global phase 3 clinical research study evaluating the safety and efficacy of seladelpar, an investigational drug for people already diagnosed with PBC who have been using ursodeoxycholic acid (also known as UDCA or ursodiol) but have not achieved the recommended treatment goal or cannot tolerate UDCA. PBC is a chronic, serious and potentially life-threatening liver disease.

Key Points: 
  • The most common early symptoms of PBC are itching (pruritus) and fatigue,1 which can be very debilitating for some people.
  • Bon Secours Liver Institute of Richmond, a part of the Bon Secours Health System of Virginia, provides medical care for patients with all forms of acute and chronic liver disease.
  • This includes treatment for all forms of chronic viral hepatitis, fatty liver disease, liver cirrhosis and its complications, and hepatocellular carcinoma.
  • The mission of the Liver Institute ofRichmond is to offer the best and most comprehensive care for patients with liver disease.

CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences

Retrieved on: 
Thursday, February 3, 2022
Bilirubin, Private Securities Litigation Reform Act, CE marking, Professional corporation, Army of the United States, Risk, Union, National Heart, Lung, and Blood Institute, Ticagrelor, Liver disease, Patient, NASDAQ, HHS, SEC, National, Cytokine adsorbing column, Adsorption, Twitter, Cytosorbents Corporation, United States Special Operations Command, Cytokine release syndrome, COVID-19, Death, Trauma, Investor relations, Facebook, Rivaroxaban, Air Force Materiel Command, Adult, DARPA, Federal, Annual report, Company, Blood, United, Manifest and latent functions and dysfunctions, Myoglobin, Cardiopulmonary bypass, Office of Inspector General, U.S. Department of Health and Human Services, DOAC, NIH, NHLBI, Safe, U.S. Department of Defense Strategy for Operating in Cyberspace, FDA, Lung, Event, Conference, SOCOM, Judgement, Pharmaceutical industry

MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.

Key Points: 
  • MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.
  • On Thursday, February 17, 2022, Dr. Phillip Chan, CytoSorbents' Chief Executive Officer, will participate in a virtual fireside chat during the 11th Annual SVB Leerink Global Healthcare Conference at 10:00 a.m. Eastern time.
  • An archived recording of CytoSorbents' presentations at both investor conferences will be available under the Investor Relations portion of the Company's website at Events & Presentations - Cytosorbents , and will be available for 30 days.
  • CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification.